concept

DS-A9BDD726D951

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DS-A9BDD726D951: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

60Connections

0Hypotheses

0Analyses

30Outgoing

30Incoming

0Experiments

0Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	DS-A9BDD726D951

Pathway Diagram

graph TD
    DS_A9BDD726D951[DS-A9BDD726D951]
    DS_A9BDD726D951 -->|data_in| APOE4_impairs_amyloid_clearanc[APOE4 impairs amyloid clearance via blood-brain barrier]
    DS_A9BDD726D951 -->|data_in| Aducanumab_removes_amyloid_pla[Aducanumab removes amyloid plaques but EMERGE/ENGAGE trials gave conflicting efficacy results]
    DS_A9BDD726D951 -->|data_in| Amyloid_oligomers_impair_LTP_i[Amyloid oligomers impair LTP in hippocampal slices]
    DS_A9BDD726D951 -->|data_in| A_42_A_40_ratio_is_a_stronger_[Aβ42/Aβ40 ratio is a stronger biomarker than Aβ42 alone]
    DS_A9BDD726D951 -->|data_in| Bell2012[Bell2012]
    DS_A9BDD726D951 -->|data_in| GBA1_mutations_are_the_most_co[GBA1 mutations are the most common genetic risk factor for Parkinson disease]
    DS_A9BDD726D951 -->|data_in| Huang2017[Huang2017]
    DS_A9BDD726D951 -->|data_in| Janelidze2021[Janelidze2021]
    DS_A9BDD726D951 -->|data_in| Kamenetz2003[Kamenetz2003]
    DS_A9BDD726D951 -->|data_in| Lecanemab_slows_clinical_decli[Lecanemab slows clinical decline in early AD at 18 months]
    APOE4_impairs_amyloid_clearanc -->|provides_data_for| DS_A9BDD726D951
    Aducanumab_removes_amyloid_pla -->|provides_data_for| DS_A9BDD726D951
    Amyloid_oligomers_impair_LTP_i -->|provides_data_for| DS_A9BDD726D951
    A_42_A_40_ratio_is_a_stronger_ -->|provides_data_for| DS_A9BDD726D951
    Bell2012 -->|provides_data_for| DS_A9BDD726D951
    GBA1_mutations_are_the_most_co -->|provides_data_for| DS_A9BDD726D951
    Huang2017 -->|provides_data_for| DS_A9BDD726D951
    Janelidze2021 -->|provides_data_for| DS_A9BDD726D951
    Kamenetz2003 -->|provides_data_for| DS_A9BDD726D951
    Lecanemab_slows_clinical_decli -->|provides_data_for| DS_A9BDD726D951

Outgoing (30)

Target	Relation	Type	Str
APOE4 impairs amyloid clearance via blood-brain barrier	data_in	entity	1.00
Amyloid oligomers impair LTP in hippocampal slices	data_in	entity	1.00
Aβ42/Aβ40 ratio is a stronger biomarker than Aβ42 alone	data_in	entity	1.00
Bell2012	data_in	entity	1.00
GBA1 mutations are the most common genetic risk factor for Parkinson disease	data_in	entity	1.00
Huang2017	data_in	entity	1.00
Janelidze2021	data_in	entity	1.00
Kamenetz2003	data_in	entity	1.00
Lecanemab slows clinical decline in early AD at 18 months	data_in	entity	1.00
Mattsson-Carlgren2020	data_in	entity	1.00
Meyer-Luehmann2006	data_in	entity	1.00
Misfolded Aβ acts as a seed for prion-like propagation	data_in	entity	1.00
Narendra2008	data_in	entity	1.00
Neuroinflammation precedes tau deposition in early AD	data_in	entity	1.00
PU.1 (SPI1) regulates onset age in AD through microglial gene expression	data_in	entity	1.00
Pascoal2021	data_in	entity	1.00
Phospho-tau 217 (p-tau217) predicts amyloid pathology with high accuracy	data_in	entity	1.00
Rogaeva2007	data_in	entity	1.00
Sevigny2016	data_in	entity	1.00
Sidransky2009	data_in	entity	1.00
SorLA (SORL1) deficiency increases Aβ42 production	data_in	entity	1.00
Synaptic Aβ release is activity-dependent	data_in	entity	1.00
TREM2 loss impairs microglial clustering around amyloid plaques	data_in	entity	1.00
Tau propagation follows anatomical connectivity	data_in	entity	1.00
Walsh2002	data_in	entity	1.00
Wang2015	data_in	entity	1.00
de Calignon2012	data_in	entity	1.00
van Dyck2023	data_in	entity	1.00
Aducanumab removes amyloid plaques but EMERGE/ENGAGE trials gave conflicting efficacy results	data_in	entity	1.00
Mitophagy dysfunction drives Parkinson disease pathology via PINK1/Parkin pathway	data_in	entity	1.00

Incoming (30)

Source	Relation	Type	Str
APOE4 impairs amyloid clearance via blood-brain barrier	provides_data_for	entity	1.00
Amyloid oligomers impair LTP in hippocampal slices	provides_data_for	entity	1.00
Aβ42/Aβ40 ratio is a stronger biomarker than Aβ42 alone	provides_data_for	entity	1.00
Bell2012	provides_data_for	entity	1.00
GBA1 mutations are the most common genetic risk factor for Parkinson disease	provides_data_for	entity	1.00
Huang2017	provides_data_for	entity	1.00
Janelidze2021	provides_data_for	entity	1.00
Kamenetz2003	provides_data_for	entity	1.00
Lecanemab slows clinical decline in early AD at 18 months	provides_data_for	entity	1.00
Mattsson-Carlgren2020	provides_data_for	entity	1.00
Meyer-Luehmann2006	provides_data_for	entity	1.00
Misfolded Aβ acts as a seed for prion-like propagation	provides_data_for	entity	1.00
Narendra2008	provides_data_for	entity	1.00
Neuroinflammation precedes tau deposition in early AD	provides_data_for	entity	1.00
PU.1 (SPI1) regulates onset age in AD through microglial gene expression	provides_data_for	entity	1.00
Pascoal2021	provides_data_for	entity	1.00
Phospho-tau 217 (p-tau217) predicts amyloid pathology with high accuracy	provides_data_for	entity	1.00
Rogaeva2007	provides_data_for	entity	1.00
Sevigny2016	provides_data_for	entity	1.00
Sidransky2009	provides_data_for	entity	1.00
SorLA (SORL1) deficiency increases Aβ42 production	provides_data_for	entity	1.00
Synaptic Aβ release is activity-dependent	provides_data_for	entity	1.00
TREM2 loss impairs microglial clustering around amyloid plaques	provides_data_for	entity	1.00
Tau propagation follows anatomical connectivity	provides_data_for	entity	1.00
Walsh2002	provides_data_for	entity	1.00
Wang2015	provides_data_for	entity	1.00
de Calignon2012	provides_data_for	entity	1.00
van Dyck2023	provides_data_for	entity	1.00
Aducanumab removes amyloid plaques but EMERGE/ENGAGE trials gave conflicting efficacy results	provides_data_for	entity	1.00
Mitophagy dysfunction drives Parkinson disease pathology via PINK1/Parkin pathway	provides_data_for	entity	1.00

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning DS-A9BDD726D951 in their description or question text

No additional research found